Oligodendroglioma - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 68

Oligodendroglioma - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Oligodendroglioma - Pipeline Review, Q2 2011', provides an overview of the Oligodendroglioma therapeutic pipeline. This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. 'Oligodendroglioma - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oligodendroglioma.
- A review of the Oligodendroglioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oligodendroglioma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Oligodendroglioma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oligodendroglioma Overview
Therapeutics Development
An Overview of Pipeline Products for Oligodendroglioma
Oligodendroglioma Therapeutics under Development by Companies
Oligodendroglioma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Oligodendroglioma Therapeutics - Products under Development by Companies
Oligodendroglioma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Oligodendroglioma Therapeutics Development
Merck & Co., Inc.
NeoPharm, Inc.
Oligodendroglioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cintredekin Besudotox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temodal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPT-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tandutinib + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tandutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGFRvIII Peptide Vaccination - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Busulfan + Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Busulfan + Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + mercaptopurine + streptozocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide vaccine + Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide vaccine + Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protracted Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aminolevulinic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temodar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib hydrochloride + Isotretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procarbazine + Lomustine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Tumor Cell Vaccine + Sargramostim + Muromonab-CD3 + Aldesleukin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligodendroglioma Therapeutics – Drug Profile Updates
Oligodendroglioma Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Oligodendroglioma, Q2 2011
Products under Development for Oligodendroglioma – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Merck & Co., Inc., 2011
NeoPharm, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Oligodendroglioma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Oligodendroglioma, Q2 2011
Products under Development for Oligodendroglioma – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Oligodendroglioma - Pipeline Review, Q4 2010
• Nausea - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Other Hematological Disorders - Pipeline Review, H2 2012
• Ageing - Pipeline Review, H2 2012
• Neurofibromatoses - Pipeline Review, H2 2012
• Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2012